AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors

 
• By Sten Stovall
Data
AstraZeneca, FibroGen will start talks soon with the FDA aimed at regulatory submissions of roxadustat • Source: Shutterstock

More from Clinical Trials

More from R&D